Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

22.9K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
22.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

3.4K
3.4K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.1K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics.

Cytotherapy·2024
Same author

Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.

Cells·2024
Same author

Making NSC and Neurons from Patient-Derived Tissue Samples.

Methods in molecular biology (Clifton, N.J.)·2019
Same author

Special issue on stem cell and tissue engineering in development, disease, and repair.

Developmental dynamics : an official publication of the American Association of Anatomists·2018
Same author

Exome sequencing in families with severe mental illness identifies novel and rare variants in genes implicated in Mendelian neuropsychiatric syndromes.

Psychiatry and clinical neurosciences·2018
Same author

Developing two reference control samples for the Indian population.

Stem cell research·2018
Same journal

Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations.

Stem cell reports·2026
Same journal

Integration of the naive pluripotency gene network with the response to GSK3 inhibition by Tcf7l1-driven enhancer decommissioning.

Stem cell reports·2026
Same journal

Neural stem cells as potential mediators of prenatal dietary stress through epigenetic mechanisms.

Stem cell reports·2026
Same journal

BDNF regulates pituitary stem cell engagement toward precursor state.

Stem cell reports·2026
Same journal

Atg5 deficiency alters myofibroblast accumulation and alveolar regeneration in lung fibrosis.

Stem cell reports·2026
Same journal

aPKC-ζ III promotes trophoblast fusion by altering Par-3 interactions with Hippo signaling kinase LATS1.

Stem cell reports·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

7.9K

iPSC-Based cell therapy: an important step forward.

Mahendra Rao1

  • 1Director, NIH Center for Regenerative Medicine, 50 South Drive, Bethesda, MD 20892 USA.

Stem Cell Reports
|December 10, 2013
PubMed
Summary
This summary is machine-generated.

Transplanting induced pluripotent stem cells (iPSC) from a matched donor prevents immune rejection. However, using HLA-mismatched iPSC derivatives triggers an immune response, impacting cell therapy development.

More Related Videos

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.2K
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
10:57

Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells

Published on: October 24, 2019

11.4K

Related Experiment Videos

Last Updated: May 5, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

7.9K
Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.2K
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
10:57

Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells

Published on: October 24, 2019

11.4K

Area of Science:

  • Immunology
  • Stem Cell Biology
  • Regenerative Medicine

Background:

  • Induced pluripotent stem cells (iPSC) offer potential for cell therapy.
  • Immune responses to transplanted cells are a major challenge.
  • HLA matching is critical for allogeneic transplantation.

Purpose of the Study:

  • To evaluate the immunogenicity of donor-matched versus HLA-mismatched iPSC derivatives.
  • To assess the implications of these findings for iPSC-based cell therapy.

Main Methods:

  • Transplantation of donor-matched iPSC derivatives.
  • Transplantation of HLA-mismatched iPSC derivatives.
  • Monitoring for immune responses post-transplantation.

Main Results:

  • Donor-matched iPSC derivatives did not elicit an immune response.
  • HLA-mismatched iPSC derivatives induced a clear immune response.
  • Demonstrated the critical role of HLA compatibility in iPSC transplantation.

Conclusions:

  • HLA matching is essential for successful iPSC-based cell therapies.
  • Future strategies must address immune compatibility for clinical translation.
  • These findings guide the advancement of regenerative medicine using iPSCs.